

Claims

1. A recombinant rhabdovirus encoding in its genome at least one CD80 extracellular domain Fc-fusion protein or a functional variant thereof, wherein the CD80 extracellular domain Fc-fusion protein comprises the extracellular domain of CD80 and further comprises the Fc domain of an IgG.
2. The recombinant rhabdovirus according to claim 1, wherein the CD80 extracellular domain Fc-fusion protein is selected from the group comprising:
 - (i) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1,
 - (ii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1,
 - (iii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
 - (iv) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1 and the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
 - (v) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain consists of amino acids 1-207 of SEQ ID NO:4 or has at least 80% identity to amino acids 1-207 of SEQ ID NO:4 and the Fc domain consists of amino acids 208-433 of SEQ ID NO:4 or has at least 80% identity to amino acids 208-433 of SEQ ID NO:4,
 - (vi) a CD80 extracellular domain Fc-fusion protein according to any of (i)-(v) further comprising a signal peptide sequence, and
 - (vii) a CD80 extracellular domain Fc-fusion protein, comprising SEQ ID NO:3 or having at least 80% identity to SEQ ID NO:3.
3. The recombinant rhabdovirus according to any of claims 1 to 2 which is a vesiculovirus.
4. The recombinant rhabdovirus according to claim 3, wherein the vesiculovirus is selected from the group comprising: Vesicular stomatitis alagoas virus (VSAV), Carajás virus (CJSV), Chandipura virus (CHPV), Cocal virus (COCV), Vesicular stomatitis Indiana virus (VSIV), Isfahan virus (ISFV), Maraba virus (MARAV), Vesicular stomatitis New Jersey virus (VSNJV), or Piry virus (PIRYV).

5. The recombinant rhabdovirus according to claim 3, which is a vesicular stomatitis virus, preferably a Vesicular stomatitis Indiana virus (VSIV) or Vesicular stomatitis New Jersey virus (VSNJV).
6. The recombinant rhabdovirus according to any of claims 1 to 5, wherein the rhabdovirus is replication-competent.
7. The recombinant rhabdovirus according to any of claim 1 to 6, wherein the rhabdovirus
 - (i) lacks a functional gene coding for glycoprotein G, and/or
 - (ii) lacks a functional glycoprotein G.
8. The recombinant rhabdovirus according to claim 7, wherein
 - (i) the gene coding for the glycoprotein G is replaced by the gene coding for the glycoprotein GP of another virus, and/or
 - (ii) the glycoprotein G is replaced by the glycoprotein GP of another virus.
9. The recombinant rhabdovirus according to claim 8, wherein
 - (i) the gene coding for the glycoprotein G is replaced by the gene coding for the glycoprotein GP of an arenavirus, and/or
 - (ii) the glycoprotein G is replaced by the glycoprotein GP of an arenavirus.
10. The recombinant rhabdovirus according to any of claims 8 to 9, wherein
 - (i) the gene coding for the glycoprotein G is replaced by the gene coding for the glycoprotein GP of Dandenong virus or Mopeia virus, and/or
 - (ii) the glycoprotein G is replaced by the glycoprotein GP of Dandenong virus or Mopeia virus.
11. The recombinant rhabdovirus according to any of claims 7 to 9, wherein
 - (i) the gene coding for the glycoprotein G is replaced by the gene coding for the glycoprotein GP of Lymphocyte choriomeningitis virus (LCMV), and/or
 - (ii) the glycoprotein G is replaced by the glycoprotein GP of LCMV.
12. A recombinant vesicular stomatitis virus encoding in its genome at least one CD80 extracellular domain Fc-fusion protein or a functional variant thereof, wherein the CD80 extracellular domain Fc-fusion protein comprises the extracellular domain of CD80 and further comprises the Fc domain of an IgG.
13. The recombinant vesicular stomatitis virus according to claim 12, wherein the CD80 extracellular domain Fc-fusion protein is selected from the group comprising:
 - (i) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1,

- (ii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1,
- (iii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
- (iv) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1 and the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
- (v) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain consists of amino acids 1-207 of SEQ ID NO:4 or has at least 80% identity to amino acids 1-207 of SEQ ID NO:4 and the Fc domain consists of amino acids 208-433 of SEQ ID NO:4 or has at least 80% identity to amino acids 208-433 of SEQ ID NO:4,
- (vi) a CD80 extracellular domain Fc-fusion protein according to any of (i)-(v) further comprising a signal peptide sequence, and
- (vii) a CD80 extracellular domain Fc-fusion protein, comprising SEQ ID NO:3 or having at least 80% identity to SEQ ID NO:3,

wherein the gene coding for the glycoprotein G of the recombinant vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of Lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV.

- 14. The recombinant vesicular stomatitis virus according to claim 13, wherein the genome encodes for a CD80 extracellular domain fused to the Fc domain of an IgG1.
- 15. The recombinant vesicular stomatitis virus according to claim 14, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1.
- 16. The recombinant vesicular stomatitis virus according to claim 14, wherein the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2.
- 17. The recombinant vesicular stomatitis virus according to claim 14, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1 and the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2.

18. The recombinant vesicular stomatitis virus according to any of claims 14 to 17 further comprising a signal peptide sequence.
19. The recombinant vesicular stomatitis virus according to claim 13, wherein the genome encodes for a CD80 extracellular domain Fc-fusion protein comprising SEQ ID NO:3 or having at least 80% identity to SEQ ID NO:3.
20. A recombinant vesicular stomatitis virus, encoding in its genome at least for a vesicular stomatitis virus nucleoprotein (N), large protein (L), phosphoprotein (P), matrix protein (M), glycoprotein (G) and at least one CD80 extracellular domain Fc-fusion protein or a functional variant thereof, wherein the CD80 extracellular domain Fc-fusion protein comprises the extracellular domain of CD80 and further comprises the Fc domain of an IgG.
21. The recombinant vesicular stomatitis virus according to claim 20, wherein the nucleoprotein (N) comprises an amino acid sequence as set forth in SEQ ID NO:7 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7.
22. The recombinant vesicular stomatitis virus according to any of claims 20 or 21, wherein the phosphoprotein (P) comprises an amino acid sequence as set forth in SEQ ID NO:8 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8.
23. The recombinant vesicular stomatitis virus according to any of claims 20 to 22, wherein the large protein (L) comprises an amino acid sequence as set forth in SEQ ID NO:9 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9.
24. The recombinant vesicular stomatitis virus according to any of claims 20 to 23, wherein the matrix protein (M) comprises an amino acid sequence as set forth in SEQ ID NO:10 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:10.
25. The recombinant vesicular stomatitis virus according to any of claims 20 to 24, wherein:
- the nucleoprotein (N) comprises an amino acid sequence as set forth in SEQ ID NO:7 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,

- 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7,
- wherein the phosphoprotein (P) comprises an amino acid sequence as set forth in SEQ ID NO:8 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8,
 - wherein the large protein (L) comprises an amino acid sequence as set forth in SEQ ID NO:9 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, and
 - the matrix protein (M) comprises an amino acid sequence as set forth in SEQ ID NO:10 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:10.
26. The recombinant vesicular stomatitis virus according to any of claims 20 to 25, which is replication-competent.
27. The recombinant vesicular stomatitis virus according to any of claims 20 to 26, which
- (i) lacks a functional gene coding for glycoprotein G, and/or
 - (ii) lacks a functional glycoprotein G.
28. The recombinant vesicular stomatitis virus according to any of claims 20 to 27, wherein
- (i) the gene coding for the glycoprotein G is replaced by the gene coding for the glycoprotein GP of another virus, and/or
 - (ii) the glycoprotein G is replaced by the glycoprotein GP of another virus.
29. The recombinant vesicular stomatitis virus according to any of claims 20 to 28, wherein
- (i) the gene coding for the glycoprotein G is replaced by the gene coding for the glycoprotein GP of Lymphocyte choriomeningitis virus (LCMV), and/or
 - (ii) the glycoprotein G is replaced by the glycoprotein GP of LCMV.
30. The recombinant vesicular stomatitis virus according to any of claims 20 to 29, wherein the CD80 extracellular domain Fc-fusion protein is selected from the group comprising
- (i) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1,
 - (ii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the

CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1,

- (iii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
- (iv) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1 and the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
- (v) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain consists of amino acids 1-207 of SEQ ID NO:4 or has at least 80% identity to amino acids 1-207 of SEQ ID NO:4 and the Fc domain consists of amino acids 208-433 of SEQ ID NO:4 or has at least 80% identity to amino acids 208-433 of SEQ ID NO:4,
- (vi) a CD80 extracellular domain Fc-fusion protein according to any of (i)-(v) further comprising a signal peptide sequence, and
- (vii) a CD80 extracellular domain Fc-fusion protein, comprising SEQ ID NO:3 or having at least 80% identity to SEQ ID NO:3.

31. A recombinant vesicular stomatitis virus encoding in its genome a vesicular stomatitis virus nucleoprotein (N), large protein (L), phosphoprotein (P), matrix protein (M), glycoprotein (G) and at least one CD80 extracellular domain Fc-fusion protein or a functional variant thereof, wherein the CD80 extracellular domain Fc-fusion protein comprises the extracellular domain of CD80 and further comprises the Fc domain of an IgG and is selected from the group comprising:

- (i) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1,
- (ii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1,
- (iii) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,
- (iv) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain comprises or consists of SEQ ID NO:1 or has at least 80% identity to SEQ ID NO:1 and the Fc domain comprises or consists of SEQ ID NO:2 or has at least 80% identity to SEQ ID NO:2,

- (v) a CD80 extracellular domain Fc-fusion protein, comprising a CD80 extracellular domain fused to the Fc domain of an IgG1, wherein the CD80 extracellular domain consists of amino acids 1-207 of SEQ ID NO:4 or has at least 80% identity to amino acids 1-207 of SEQ ID NO:4 and the Fc domain consists of amino acids 208-433 of SEQ ID NO:4 or has at least 80% identity to amino acids 208-433 of SEQ ID NO:4,
- (vi) a CD80 extracellular domain Fc-fusion protein according to any of (i)-(v) further comprising a signal peptide sequence, and
- (vii) a CD80 extracellular domain Fc-fusion protein, comprising SEQ ID NO:3 or having at least 80% identity to SEQ ID NO:3,

wherein, the gene coding for the glycoprotein G of the vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV, and wherein








- the nucleoprotein (N) comprises an amino acid as set forth in SEQ ID NO:7 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7,
- the phosphoprotein (P) comprises an amino acid as set forth in SEQ ID NO:8 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8,
- the large protein (L) comprises an amino acid as set forth in SEQ ID NO:9 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, and
- the matrix protein (M) comprises an amino acid as set forth in SEQ ID NO:10 or a functional variant at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:10.







32. A pharmaceutical composition, characterized in that the composition comprises a recombinant rhabdovirus according to any of claims 1 to 11 or a recombinant vesicular stomatitis virus according to any of claims 12 to 31.







33. A recombinant rhabdovirus according to any of claims 1 to 11, a recombinant vesicular stomatitis virus according to any of claims 12 to 31 or a pharmaceutical composition according to claim 32 for use as a medicament.







34. A recombinant rhabdovirus according to any of claims 1 to 11, a recombinant vesicular stomatitis virus according to any of claims 12 to 31 or a pharmaceutical composition according to claim 32 for use in the treatment of cancer, preferably solid cancers.


35. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus or the pharmaceutical composition for use according to claim 34, wherein the solid cancer is selected from the list comprising: reproductive tumor, an ovarian tumor, a testicular tumor, an endocrine tumor, a gastrointestinal tumor, a pancreatic tumor, a liver tumor, a kidney tumor, a colon tumor, a colorectal tumor, a bladder tumor, a prostate tumor, a skin tumor, melanoma, a respiratory tumor, a lung tumor, a breast tumor, a head & neck tumor, a head and neck squamous-cell carcinoma (HNSCC) and a bone tumor.
36. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus or the pharmaceutical composition for use according to any of claims 33 to 35, wherein the recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition is to be administered intratumorally or intravenously.
37. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus or the pharmaceutical composition for use according to any of claims 34 to 36, wherein the recombinant rhabdovirus, the recombinant vesicular stomatitis virus or the pharmaceutical composition is to be administered at least once intratumorally and subsequently intravenously.
38. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus or the pharmaceutical composition for use according to claim 37, wherein the subsequent intravenous administration is given 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days after the initial intratumoral administration.
39. A composition comprising a recombinant rhabdovirus or a recombinant vesicular stomatitis virus according to any of the preceding claims and further a PD-1 pathway inhibitor or a SMAC mimetic.
40. The composition according to claim 39, wherein the PD-1 pathway inhibitor is an antagonistic antibody, which is directed against PD-1 or PD-L1.
41. The composition according to claim 39, wherein the SMAC mimetic is selected from the group consisting of any one of compounds 1 to 26:

1	
2	
3	
4	
5	
6	
7	

8	
9	
10	
11	
12	
13	

14	
15	
16	
17	
18	
19	

20	
21	
22	
23	
24	
25	



or a pharmaceutically acceptable salt of one of these compounds.

42. The composition according to claim 39, wherein the PD-1 pathway inhibitor is an antagonist selected from the group consisting of pembrolizumab, nivolumab, pidilizumab, atezolizumab, avelumab, durvalumab, PDR-001, PD1-1, PD1-2, PD1-3, PD1-4 and PD1-5.
43. A kit of parts comprising:
- a recombinant rhabdovirus, a recombinant vesicular stomatitis virus or a pharmaceutical composition as defined in any of the preceding claims, and
 - a PD-1 pathway inhibitor or SMAC mimetic as defined in any of the preceding claims.
44. A recombinant rhabdovirus, a recombinant vesicular stomatitis virus, or a pharmaceutical composition for use according to any of claims 33 to 35 in combination with a PD-1 pathway inhibitor or a SMAC mimetic.
45. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition for use according to claim 44, wherein the recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition is administered concomitantly, sequentially or alternately with the PD-1 pathway inhibitor or the SMAC mimetic.
46. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition for use according to claims 44 to 45, wherein the SMAC mimetic is selected from the group consisting of any one of compounds 1 to 26 according to claim 41 or a pharmaceutically acceptable salt of one of these compounds.
47. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition for use according to claims 44 to 45, wherein the PD-1 pathway inhibitor is selected from the group consisting of pembrolizumab, nivolumab, pidilizumab, atezolizumab, avelumab, durvalumab, PDR-001, PD1-1, PD1-2, PD1-3, PD1-4 and PD1-5.

48. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition for use according to any of claims 44 to 46, wherein the recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition is administered via a different administration route than the PD-1 pathway inhibitor or the SMAC mimetic.
49. The recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition for use according to any of claims 44 to 46, wherein the recombinant rhabdovirus, the recombinant vesicular stomatitis virus, or the pharmaceutical composition are administered at least once intratumorally and the PD-1 pathway inhibitor or the SMAC mimetic is administered intravenously.
50. A virus producing cell, characterized in that the cell produces a recombinant rhabdovirus or recombinant vesicular stomatitis virus according to any of the preceding claims.
51. The virus producing cell of claim 50, characterized in that the cell is a Vero cell, a HEK cell, a HEK293 cell, a Chinese hamster ovary cell (CHO), or a baby hamster kidney (BHK) cell.
52. A recombinant rhabdovirus encoding in its RNA genome at least one CD80 extracellular domain Fc-fusion protein or a functional variant thereof, wherein the CD80 extracellular domain Fc-fusion protein comprises the extracellular domain of CD80 and further comprises the Fc domain of an IgG, wherein the RNA genome of the recombinant rhabdovirus comprises or consists of a coding sequence identical or at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 24.